This episode breaks down the FDA's transformative final guidance on medical device cybersecurity issued in September 2023. We explore the new legal authorities granted by the Food and Drug Omnibus Reform Act (FDORA), the definition of a "cyber device," and the critical requirements for premarket submissions, including the Secure Product Development Framework (SPDF) and the mandatory Software Bill of Materials (SBOM). Learn what your company must do to avoid a "Refuse to Accept" (RTA) notice and ensure compliance throughout the total product lifecycle. Key Questions: • What are the main requirements of the FDA's September 2023 cybersecurity guidance? • How does the Food and Drug Omnibus Reform Act (FDORA) empower the FDA? • What defines a "cyber device" under the new law? • Why is a Secure Product Development Framework (SPDF) essential for new device submissions? • What must be included in a Software Bill of Materials (SBOM)? • What happens if a premarket submission fails to meet the new cybersecurity criteria? • How does the guidance impact a manufacturer's post-market responsibilities? • What enforcement actions can the FDA now take for non-compliance? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.